Literature DB >> 18202690

The state of innovation in drug development.

I Kola1.   

Abstract

The pharmaceutical industry is facing tremendous pressure, not only from payers but as a result of public perception, regulatory hurdles, and the intricacies of research and development (R&D). The latter two are significant in that they affect the number of drugs that may be registered by regulatory authorities, the time to discover and develop drugs, and the cost of drug development. Because drug development has been stagnant in terms of innovation, there exists huge potential for innovation. Failure to innovate drug development will render the "big pharma" model unsustainable.

Mesh:

Year:  2008        PMID: 18202690     DOI: 10.1038/sj.clpt.6100479

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  64 in total

1.  Early human screening of medications to treat drug addiction: novel paradigms and the relevance of pharmacogenetics.

Authors:  K A Perkins; C Lerman
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

Review 2.  Induced pluripotent stem cells--opportunities for disease modelling and drug discovery.

Authors:  Marica Grskovic; Ashkan Javaherian; Berta Strulovici; George Q Daley
Journal:  Nat Rev Drug Discov       Date:  2011-11-11       Impact factor: 84.694

Review 3.  How to improve R&D productivity: the pharmaceutical industry's grand challenge.

Authors:  Steven M Paul; Daniel S Mytelka; Christopher T Dunwiddie; Charles C Persinger; Bernard H Munos; Stacy R Lindborg; Aaron L Schacht
Journal:  Nat Rev Drug Discov       Date:  2010-02-19       Impact factor: 84.694

Review 4.  Challenges in sexual medicine.

Authors:  Selim Cellek; Annamaria Giraldi
Journal:  Nat Rev Urol       Date:  2012-07-10       Impact factor: 14.432

5.  Quantitative-qualitative data acquisition using a benchtop Orbitrap mass spectrometer.

Authors:  Kevin P Bateman; Markus Kellmann; Helmut Muenster; Robert Papp; Lester Taylor
Journal:  J Am Soc Mass Spectrom       Date:  2009-03-06       Impact factor: 3.109

6.  Drug design and discovery: translational biomedical science varies among countries.

Authors:  Ian N Weaver; Donald F Weaver
Journal:  Clin Transl Sci       Date:  2013-04-19       Impact factor: 4.689

7.  A transfection method of PS-asODNs targeting ANGPTL4 in multicellular structures of hepatocarcinoma cell line.

Authors:  Q Kong; G Wu; L Han; Z Zhang; J Du; W Sun; L Cao
Journal:  Cancer Gene Ther       Date:  2015-04-24       Impact factor: 5.987

8.  Engineering challenges for instrumenting and controlling integrated organ-on-chip systems.

Authors:  John P Wikswo; Frank E Block; David E Cliffel; Cody R Goodwin; Christina C Marasco; Dmitry A Markov; David L McLean; John A McLean; Jennifer R McKenzie; Ronald S Reiserer; Philip C Samson; David K Schaffer; Kevin T Seale; Stacy D Sherrod
Journal:  IEEE Trans Biomed Eng       Date:  2013-02-01       Impact factor: 4.538

9.  Heterotransplant mouse model cohorts of human malignancies: A novel platform for Systematic Preclinical Efficacy Evaluation of Drugs (SPEED).

Authors:  Ashutosh K Pathak; Manisha Bhutani; Pierre Saintigny; Li Mao
Journal:  Am J Transl Res       Date:  2009-01-01       Impact factor: 4.060

Review 10.  Bioreactor engineering of stem cell environments.

Authors:  Nina Tandon; Darja Marolt; Elisa Cimetta; Gordana Vunjak-Novakovic
Journal:  Biotechnol Adv       Date:  2013-03-24       Impact factor: 14.227

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.